Thermo Fisher Scientific (TMO) Announces Fiscal Q1 2026 Results

Thermo Fisher Scientific (NYSE:TMO) reported strong fiscal Q1 2026 results, with revenue rising 6% to $11.01 billion and GAAP diluted EPS growing 11% to $4.43. The company also introduced several new high-impact scientific instruments and systems. An analyst from BofA raised their target for TMO, citing a recovery in biopharma.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin